Abstract
Abstract
Background
Hepatitis C virus (HCV) infection is a worldwide disease. HCV-related arthritis is one of the extrahepatic manifestations of the disease. The treatment of chronic HCV has been revolutionized with the introduction of oral direct-acting antiviral (DAA) drugs. We aim to determine the outcomes of treatment by the combination of sofosbuvir-daclatasvir with or without ribavirin in patients with HCV-related arthritis.
Results
Post-therapy, all group I patients had sustained viral response. Significant improvement of the outcome parameters was found 12 weeks post-treatment in group I compared to baseline and group II. Complete and partial remission of articular symptoms in group I patients was observed in 80% and 5%, respectively, while 85% of patients in group II showed no remission. Few mild side effects were encountered with therapy.
Conclusion
The combination of sofosbuvir-daclatasvir with or without ribavirin is an effective and safe therapy for eradication of HCV infection and amelioration of HCV-related arthritis.
Publisher
Springer Science and Business Media LLC
Reference38 articles.
1. Thomas DL (2013) Global control of hepatitis C: where challenge meets opportunity. Nat Med 19(7):850
2. Jimenez AP, Eldin NS, Rimlinger F, El-Daly M, El-Hariri H, El-Hoseiny M et al (2010) HCV iatrogenic and intrafamilial transmission in Greater Cairo, Egypt. Gut 59(11):1554–1560
3. Abdel-Aziz F, Habib M, Mohamed MK et al (2000) Hepatitis C virus (HCV) infection in a community in the Nile Delta: population description and HCV prevalence. Hepatology. 32(1):111–115
4. El-Zanaty F, Way A. Egypt Demographic and Health Survey 2008. Cairo: Ministry of Health, El-Zanaty and Associates and Macro International; 2009. p. 431.
5. Ministry of Health and Population [Egypt], El-Zanaty and Associates [Egypt], ICF International. Egypt Health Issues Survey 2015. Cairo, Rockville, MD: Ministry of Health and Population, ICF International; 2015.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献